Video

Keeping the Dream Alive: Supporting Female Survivors

Barbara Bittner, RN, OCN, a finalist for the CURE® Extraordinary Healer® Award for Oncology Nursing, talked about her advocacy work with Charlene’s Dream – a community-based cancer resource center for women.

Barbara Bittner, RN, OCN, a finalist for the CURE® Extraordinary Healer® Award for Oncology Nursing and a nurse oncology navigator at AdventHealth, talked about her advocacy work with Charlene’s Dream — a community-based cancer resource center that provides information and support to help patients cope with their disease effectively.

Not only does the boutique provide educational resources, but also monthly support groups, mastectomy bras, breast prosthesis and wigs for survivors.

Bittner, a co-founder of Charlene’s Dream who ran the art therapy group, also discussed the story behind the “warm and welcoming haven for those with cancer.” The free services are available, as Bittner pointed out, to any woman with any type of cancer — not just breast cancer.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content